TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03914339

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Periodontal and orthodontic treatment
Description: Eighteen periodontally compromised patients who give be given both periodontal and orthodontic treatment
Study: NCT00443430

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Description: Methotrexate 0.5 mg/kg given by sub cutaneous injection once per week, plus placebo etanercept and and placebo prednisolone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate - etanercept - prednisolone arm
Description: methotrexate 0.5 mg/kg given by sub cutaneous injection once per week, plus etanercept 0.8 mg/kg given by sub cutaneous injection once per week, plus prednisolone, by mouth daily with decreasing dose tapered over 16 weeks.
Study: NCT00107263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Study: NCT03391440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: morinidazole
Description: morinidazole and sodium chloride injection (500 mg intravenous, twice daily for 14 days) with levofloxacin hydrochloride and sodium chloride injection (500 mg intravenous, once daily for the first week) sequential of levofloxacin hydrochloride tablets (500 mg (500 mg orally, once daily for the second week)
Study: NCT03995407

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Peptamen®
Description: Participants in the intervention arm will be categorised into those who are not currently taking oral nutritional supplement and those who are currently on oral nutritional supplements. Those who are not currently taking oral nutritional supplement will be started on Peptamen® while those who are currently on oral nutritional supplements will have to convert to Peptamen® solely. The dietician will determine the amount of Peptamen® required per day based on the recommendations of the product information. Should the participant's daily protein requirement not be met be Peptamen® alone, the dietician will recommend additional whey protein to be added in the form of Beneprotein® Instant Protein Powder. Beneprotein® is a concentrated source of high-quality whey protein that can be added to most foods, liquids or enteral formulas.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants receive usual care. They will be categorised into those who are not currently taking oral nutritional supplement and those who are currently on oral nutritional supplements (non-100% whey i.e. not on Peptamen® or Beneprotein®). They will consume their regular diet in accordance with the dietician's recommendations.
Study: NCT02408146

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional intravenous infusion pump
Description: The first group receives conventional intravenous infusion pump of patient-controlled analgesia (fentanyl citrate 20 mg/mL/kg + ondansetron hydrochloride 16 mg/8 mL + normal saline) for three days after surgery. The pump is infused continuously at the basic flow rate of 2 mL/h, 0.5 mL of bolus can be injected if the patients press the button once upon experiencing pain. The lock-out time for each bolus injection is 15 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: parecoxib
Description: The second group has oral celecoxib before surgery, then receives 40 mg parecoxib sodium intravenously guttae twice a day for three days after surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: parecoxib
Description: The second group has oral celecoxib before surgery, then receives 40 mg parecoxib sodium intravenously guttae twice a day for three days after surgery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intravenous infusion pump of patient-controlled analgesia
Description: The third group has oral celecoxib before surgery, and receives 40 mg parecoxib sodium intravenously guttae immediately after surgery, then uses new intravenous infusion pump of patient-controlled analgesia (parecoxib sodium 1 mg/mL + normal saline) for three days after surgery. The pump is infused continuously at the basic flow rate of 2 mL/h, 0.5 mL of bolus can be injected if the patients press the button once upon experiencing pain. The lock-out time for each bolus injection is 15 minutes.
Study: NCT03914339

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: periodontal treatment
Description: Eighteen periodontally compromised patients who give be given periodontal treatment alone.
Study: NCT04710693

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: CAD polyp-detection system
Description: Software will be used during the procedure to aid the detection of polyps during the procedure.
Study: NCT02408146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fentanyl citrate+ ondansetron hydrochloride + normal saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib
Study: NCT03952923

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19-CAR-T cells
Description: CD19-CAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of CAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 250mg/m2 for 3 days and take a rest for 2 days before infusion.
Study: NCT02949661

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Superficial cervical plexus block
Description: Patients will receive bilateral superficial cervical plexus block

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local wound infiltration
Description: Patients will receive local wound infiltration
Study: NCT02391727

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: SYN004
Description: subjects who have received effective treatment for their cancers are eligible
Study: NCT01299597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: 20mg single dose given alone and coadministered with SB649868 on day 8 and 12 of the 14-day repeat dose period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: 10mg single dose given alone and coadministered with SB649868 on day 12 and 14 of the 14-day repeat dose period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB649868
Description: 20mg daily given for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB649868
Description: 20mg daily given for 14 days.
Study: NCT03524365

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RYGB
Description: Roux-\&-Y Gastric Bypass (RYGB) involves the use of a surgical stapler to create a small and vertically oriented gastric pouch with a volume of 30 ml. The upper pouch is completely divided by the gastric remnant and is anastomosed to the jejunum, 75 cm distally to the Treitz's ligament , through a narrow gastrojejunal anastomosis in a Roux-en-Y fashion. Bowel continuity is restored by an entero-entero anastomosis, between the excluded biliary limb and the alimentary limb, performed at 100 cm from the gastrojejunostomy. Lifestyle modification counselling is provided to each patient.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SG
Description: The SG is created using a linear stapler with two sequential 4.8/60-mm green load firings for the antrum, followed by two or three sequential 3.5/60-mm blue loads for the remaining gastric corpus and fundus. The stapler is applied alongside a 48-Fr calibrating bougie. The resection line is performed avoiding the ''critical area'' by resecting the fundus 1.5 cm from the angle of His. Staple lines are buttressed with bovine pericardial strips. The resected stomach is grasped at the antral tip by a laparoscopic grasper and retrieved through one of the trocar sites. A methylene blue dye test by a nasogastric tube is routinely performed at the end of the procedure. The residual gastric remnant capacity is 60-80 ml. Drains are not routinely placed, and the nasogastric tube is removed at the end of the procedure. Upper gastrointestinal contrast (Gastrografin) study is performed on the first postoperative day. Lifestyle modification counselling is provided to each patient.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Intensive Lifestyle Modification
Description: Resting calorie requirements will be calculated via the Harris Benedict equation (24) and an activity factor, and subjects will be instructed not to change their activity level other than that suggested by physicians during the study. The diet will contain 1/3 kcal less than the calculated energy expenditure and 30% fat of which 10% saturated, 55% lower glycemic index carbohydrates and 15% proteins.~The participants will be encouraged to gradually increase their walking to achieve 10,000 steps per day. A moderate intensity physical activity program of 1 hour of aerobic exercise 2-3 hours per week will be recommended to all subjects. Their physical activity will be assessed by IPAQ-SF.
Study: NCT03962998

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactulose/Rhamnose solution
Description: Lactulose/Rhamnose solution administered orally followed by measurement of excreted lactulose and rhamnose in urine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MB-102
Description: MB-102 solution administered orally followed by measurement of excreted MB-102 in urine
Study: NCT01645930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Ixazomib capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone tablets
Study: NCT00797927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: quetiapine
Description: quetiapine (with equivalent dose to original antipsychotic agent) would replace the original antipsychotic agent for 28 days

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: no intervention
Description: keep the original conventional antipsychotic agent for 28 days
Study: NCT00277472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan/Hydrochlorothiazide
Description: 160/12.5 mg taken once daily orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HCTZ
Description: 25 mg taken once daily orally
Study: NCT03774017

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: one-staged hybrid operation
Description: An integrated procedure that consists of microsurgery, intraoperative DSA, endovascular intervention techniques and other assistance tools. All the procedures are performed in a one-staged operation without any intermission or any transfer of patients.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Traditional microsurgical operation
Description: The classical mode of operations in neurosurgery. The operation is performed with neurosurgical instruments and microscope. Some of assisting tools can be used in the operation, such as neuro-navigation, Doppler probe, neural electrophysiological monitoring and so on. But neither the intraoperative DSA nor endovascular intervention techniques is used in the operation
Study: NCT02020343

Intervention type: BEHAVIORAL
Intervention: taste tests
Description: Subjects undergo sham feeding in which they take a bit of food, chew it and spit it out. This test should engage sensory mechanisms which may affect intestinal signaling.

Intervention type: BEHAVIORAL
Intervention: taste tests
Description: Subjects undergo sham feeding in which they take a bit of food, chew it and spit it out. This test should engage sensory mechanisms which may affect intestinal signaling.

Intervention type: BEHAVIORAL
Intervention: taste tests
Description: Subjects undergo sham feeding in which they take a bit of food, chew it and spit it out. This test should engage sensory mechanisms which may affect intestinal signaling.
Study: NCT02868502

Intervention type: DEVICE
Intervention: Goldmann tonometer
Description: IOP measurement in the sitting position and lateral decubitus

Intervention type: DEVICE
Intervention: Goldmann tonometer
Description: IOP measurement in the sitting position and lateral decubitus
Study: NCT01800409

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AFES
Description: During the stimulation sessions electrical stimulation will be applied for 40 minutes per day, 5 days per week for a total of 8 weeks
Study: NCT02868502

Intervention type: DEVICE
Intervention: Goldmann tonometer
Description: IOP measurement in the sitting position and lateral decubitus

Intervention type: DEVICE
Intervention: Goldmann tonometer
Description: IOP measurement in the sitting position and lateral decubitus

Intervention type: DEVICE
Intervention: Goldmann tonometer
Description: IOP measurement in the sitting position and lateral decubitus

Intervention type: DEVICE
Intervention: Goldmann tonometer
Description: IOP measurement in the sitting position and lateral decubitus
Study: NCT01154036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ezetimibe 10 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ezetimibe 10 mg
Study: NCT02868502

Intervention type: DEVICE
Intervention: Pneumatonometer
Description: IOP measurement in the sitting position and lateral decubitus

Intervention type: DEVICE
Intervention: Pneumatonometer
Description: IOP measurement in the sitting position and lateral decubitus

Intervention type: DEVICE
Intervention: Pneumatonometer
Description: IOP measurement in the sitting position and lateral decubitus

Intervention type: DEVICE
Intervention: Pneumatonometer
Description: IOP measurement in the sitting position and lateral decubitus
Study: NCT02868502

Intervention type: DEVICE
Intervention: Pneumatonometer
Description: IOP measurement in the sitting position and lateral decubitus
Study: NCT01154036

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atorvastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin
Study: NCT02868502

Intervention type: DEVICE
Intervention: Pneumatonometer
Description: IOP measurement in the sitting position and lateral decubitus

Intervention type: DEVICE
Intervention: Tonopen XL
Description: IOP measurement in the sitting position and lateral decubitus

Intervention type: DEVICE
Intervention: Tonopen XL
Description: IOP measurement in the sitting position and lateral decubitus

Intervention type: DEVICE
Intervention: Tonopen XL
Description: IOP measurement in the sitting position and lateral decubitus

Intervention type: DEVICE
Intervention: Tonopen XL
Description: IOP measurement in the sitting position and lateral decubitus

Intervention type: DEVICE
Intervention: Tonopen XL
Description: IOP measurement in the sitting position and lateral decubitus
Study: NCT01154036

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atorvastatin
Study: NCT00107263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zoledronic acid
Study: NCT01154036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: rosuvastatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: rosuvastatin
Study: NCT01418092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALKS 37
Description: Capsules for oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules for oral administration
Study: NCT03795805

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: total knee arthroplasty
Description: Total knee arhroplasty

Intervention type: PROCEDURE
Group type: OTHER
Intervention: total knee arthroplasty
Description: Total knee arhroplasty

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Tourniquet limb cuff
Description: Tourniquet limb cuff and regular anesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intaarticular lidocain
Description: 20 ml of 2% lidocain application intraarticular before surgery (intraarticular lidocain)
Study: NCT03672864

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive exercise
Description: Intensive, child-initiated movement of the lower extremity: 1 hour/day, 4 days/week, 2 sessions delivered by a physical therapist, 2 delivered by a parent. All activities are play based, and exercise intensity is enhanced by small weights placed on the dorsum of the foot and the ankle of the affected limb. Intervention is delivered over 12 weeks for a target of 48 hours of training.
Study: NCT00655395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Laromustine (VNP40101M) and Ara-C
Description: 1. Laromustine 300 mg/m2 (cohort 1), 400 mg/m2 (cohort 2), 500 mg/m2 (cohort 3) IV on day 1 over 30 - 60 minutes. Laromustine will be administered approximately 3-4 hours following the start of infusional Ara C.~2. Ara C at 100 mg/m2/day as a continuous infusion daily for 7 days. Appropriate antiemetics are given during the Ara C infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Laromustine (VNP40101M) and Ara-C
Description: 1. Laromustine 300 mg/m2 (cohort 1), 400 mg/m2 (cohort 2), 500 mg/m2 (cohort 3) IV on day 1 over 30 - 60 minutes. Laromustine will be administered approximately 3-4 hours following the start of infusional Ara C.~2. Ara C at 100 mg/m2/day as a continuous infusion daily for 7 days. Appropriate antiemetics are given during the Ara C infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Laromustine (VNP40101M) and Ara-C
Description: 1. Laromustine 300 mg/m2 (cohort 1), 400 mg/m2 (cohort 2), 500 mg/m2 (cohort 3) IV on day 1 over 30 - 60 minutes. Laromustine will be administered approximately 3-4 hours following the start of infusional Ara C.~2. Ara C at 100 mg/m2/day as a continuous infusion daily for 7 days. Appropriate antiemetics are given during the Ara C infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Laromustine (VNP40101M) and Ara-C
Description: 1. Laromustine 300 mg/m2 (cohort 1), 400 mg/m2 (cohort 2), 500 mg/m2 (cohort 3) IV on day 1 over 30 - 60 minutes. Laromustine will be administered approximately 3-4 hours following the start of infusional Ara C.~2. Ara C at 100 mg/m2/day as a continuous infusion daily for 7 days. Appropriate antiemetics are given during the Ara C infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Laromustine (VNP40101M) and Ara-C
Description: 1. Laromustine 300 mg/m2 (cohort 1), 400 mg/m2 (cohort 2), 500 mg/m2 (cohort 3) IV on day 1 over 30 - 60 minutes. Laromustine will be administered approximately 3-4 hours following the start of infusional Ara C.~2. Ara C at 100 mg/m2/day as a continuous infusion daily for 7 days. Appropriate antiemetics are given during the Ara C infusion.
Study: NCT01896011

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Teriparatide 20 mcg
Description: Teriparatide 20 mcg injection pen

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 20 mcg injection pen
Study: NCT01307852

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Plastic Scintillation Detectors
Description: Radiation detectors attached to rectal balloon for each CT scan done during each radiation treatment. Treatment delivery Monday through Friday for 7 weeks.
Study: NCT02075983

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GTU®-multiHIV B clade
Description: The investigational HIV-1 vaccine GTU®-MultiHIV B clade encodes for a MultiHIV antigen (synthetic fusion protein built up by full-length polypeptides of Rev, Nef, Tat, p17 and p24 with more than 20 Th and CTL epitopes of protease, reverse transcriptase (RT) and gp160 regions of the HAN2 HIV-1 B clade.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GTU®-multiHIV B clade
Description: The investigational HIV-1 vaccine GTU®-MultiHIV B clade encodes for a MultiHIV antigen (synthetic fusion protein built up by full-length polypeptides of Rev, Nef, Tat, p17 and p24 with more than 20 Th and CTL epitopes of protease, reverse transcriptase (RT) and gp160 regions of the HAN2 HIV-1 B clade.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GTU®-multiHIV B clade
Description: The investigational HIV-1 vaccine GTU®-MultiHIV B clade encodes for a MultiHIV antigen (synthetic fusion protein built up by full-length polypeptides of Rev, Nef, Tat, p17 and p24 with more than 20 Th and CTL epitopes of protease, reverse transcriptase (RT) and gp160 regions of the HAN2 HIV-1 B clade.
Study: NCT03300089

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General anaesthesia
Description: General anaesthesia

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Regional anaesthesia
Description: Regional anaesthesia
Study: NCT00983619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-551
Description: MEDI-551 will be administered intravenously (IV) once every week in 4-week cycles until complete response, disease progression, toxicity, or another reason for treatment discontinuation will be observed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-551
Description: MEDI-551 will be administered intravenously (IV) once every week in 4-week cycles until complete response, disease progression, toxicity, or another reason for treatment discontinuation will be observed.